Applied DNA Sciences announced that the U.S. Defense Logistics Agency exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA’s counterfeit mitigation initiatives and product verification and testing programs specific to FSC 5962 microcircuits. The maximal value of the indefinite delivery contract is $1.04 million over an up to five-year performance term. The option-year exercise continues Applied DNA’s support of DLA’s counterfeit mitigation program, which has been running since 2014.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APDN:
- Applied DNA, Alphazyme conclude Linea RNAP manufacturing scale-up project
- Applied DNA Sciences partners with GenXys Health Care Systems
- Applied DNA Sciences receives approval for TR8 PGx teging service
- Applied DNA Sciences price target lowered to $1.50 from $7 at H.C. Wainwright
- Applied DNA announces notice of allowance for U.S. patent covering Linea RNAP